CRISPR Therapeutics (CRSP) In Q1 of 2024, the company reported a net loss of $116.6 million, a significant increase from the prior year's $53 million. This was due to CRSP's strategic investments in R&D and market expansion for Casgevy. Despite this, the firm boasts a robust cash reserve of approximately $2.1 billion, underpinning its capacity for sustained growth and further drug approvals expected in the next two to three years. Vertex Pharmaceuticals (NASDAQ:VRTX) is known for its pioneering cystic fibro ...

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body. All to treat cancers, blood issues, blindness, cystic fibrosis, and muscular dystrophy. All of which is creating substantial opportunities for some of the leading gene editing stocks. Plus, At the moment, there are about 7,000 diseases caused by genetic disorders. All of which occur when a mutation affects your genes. Or, when you have the wrong amount of genetic material, as ...

Heading into today, shares of the company had gained 2.02% over the past month, lagging the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22% in that time. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.51 per share and revenue of $89.43 million, indicating changes of -184.02% and -75.91%, respectively, compared to the previous year. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investor ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market pri ...

Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.37 per share, which would represent a year-over-year decline of 39.8%. Our most recent consensus estimate is calling for quarterly revenue of $8.39 million, down 88.02% from the year-ago period. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Z ...

会议主要讨论的核心内容 - 公司的投资组合包括癌症、体外非癌症、再生医学和体内基因编辑等多个垂直领域 [3][4][5][6][7] - 公司在基因编辑技术的持续创新和改进上投入了大量资源,建立了专门的CRISPR X团队 [9][10][11][12] - 公司在交付技术方面主要关注脂质纳米颗粒(LNP),并取得了在肝脏以外器官如眼睛的递送突破 [13][14][15] - 公司首个获批上市的基因编辑产品Casgevy(与Vertex合作)的上市情况良好,全球需求旺盛,且获得较好的支付报销 [16][17][18][19][20][21][22][23] - 公司正在努力开发更加温和的预处理方案,以及体内造血干细胞编辑技术,以进一步提升Casgevy的临床应用 [28][29][30][31] - 公司的体内基因编辑平台正在开展心血管疾病相关靶点的临床试验,有望在今年内获得首批数据 [33][34][35] - 公司的自身免疫疾病业务发展迅速,有望凭借其独特的同种异体CAR-T疗法在该领域取得领先地位 [37][38][39][40][41][42] - 公司的肿瘤业务持续优化,预计今年将有新一代CAR-T产品的临床数据发布,有望进一步提升公司在该领域的竞争力 [45][46][47][48][50] - 公司的再生医学业务,特别是1型糖尿病项目,也是公司的重点发展方向之一 [53][54][55] 问答环节重要的提问和回答 问题1 **Salveen Richter 提问** 公司如何在不同垂直领域间进行资本配置和R&D协同? [2] **Sam Kulkarni 回答** 公司根据CRISPR技术的优势和可以产生最大影响的疾病领域来确定投资组合 [3][4][5][6][7][8] 公司建立了专门的CRISPR X团队持续推进技术创新 [9][10][11][12] 问题2 **Salveen Richter 提问** 公司如何看待Casgevy的商业化情况,包括患者和医生反馈、渗透率以及未来优化的机会? [16][27] **Sam Kulkarni 回答** Casgevy的上市反响良好,全球需求旺盛,获得较好的支付报销支持 [17][18][19][20][21][22][23] 公司正在努力开发更加温和的预处理方案,以及体内造血干细胞编辑技术,以进一步提升Casgevy的临床应用 [28][29][30][31] 问题3 **Salveen Richter 提问** 公司的体内基因编辑平台在心血管疾病领域的进展如何,首批数据意味着什么? [32] **Sam Kulkarni 回答** 公司的体内基因编辑平台正在开展心血管疾病相关靶点的临床试验,有望在今年内获得首批数据,这将为公司后续在该领域的发展奠定基础 [33][34][35]

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this company have returned +7.8% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has gained 1.2% over this period. Now the key question is: Where could the stock be headed in the near ...

A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have added about 12% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q1 Loss Narrower-Than-Expected, Sa ...

会议主要讨论的核心内容 - 公司已经成功将CRISPR/Cas9技术商业化,推出了治疗严重型镰状细胞病和重型β地中海贫血的产品CASGEVY [2][4][5] - CASGEVY在全球范围内获批上市,目前在美国和中东等地区已有25家医疗中心启动,已有5名患者完成细胞采集 [3][6][7] - 公司与合作伙伴Vertex共同推进CASGEVY的商业化,双方分享60%和40%的利润 [5] - 公司正在快速推进多个基于CRISPR的体内基因编辑项目,包括针对ANGPTL3和Lp(a)的项目,预计今年内可能会有初步临床数据 [17][18][19][20] - 公司还在探索将CRISPR技术应用于眼科、高血压和急性卟啉症等其他适应症,并正在开发下一代基因编辑技术平台 [33][34][35] - 公司的CAR-T项目CTX112也取得了进展,预计今年内会有中期数据,未来还将在自身免疫性疾病领域开展临床试验 [36][37][38][39] 问答环节重要的提问和回答 问题1 **Maury Raycroft 提问** CASGEVY的上市初期情况如何,包括患者接受度、治疗流程时间等 [3][11][12][13] **Samarth Kulkarni 回答** - 患者对CRISPR疗法的接受度很高,大多数患者如果有选择都会选择CRISPR疗法 [7] - 从细胞采集到最终给药需要5-6个月的时间,主要是由于这是一个选择性的治疗过程,患者需要选择合适的时间窗进行治疗 [11][12][13] 问题2 **Maury Raycroft 提问** 公司在中东等地区的市场机会如何,包括定价和医疗旅游等方面 [14][15][16] **Samarth Kulkarni 回答** - 中东地区镰状细胞病患者人数可能超过美国,且当地支付能力较强,是一个重要的市场机会 [15][16] - 除中东外,亚洲也是一个潜在的市场,尽管并非所有患者都能获得保险报销,但仍有部分患者有支付能力 [16] - 公司正在寻求各种方式将产品带到这些地区患者手中,但目前美国市场仍是公司的主要关注点 [16] 问题3 **Maury Raycroft 提问** 公司的体内基因编辑项目ANGPTL3和Lp(a)的进展如何,以及与竞争对手的关系 [17][21][22][23][24][25] **Samarth Kulkarni 回答** - 这两个项目都针对已被验证的心血管风险因子,具有较大的市场空间 [18][19] - 公司预计今年内会有初步临床数据,但暂未具体指引 [20] - 如果Intellia的Lp(a)项目数据良好,将对公司及其他Lp(a)项目产生积极影响 [21][22] - 公司正在关注Lp(a)水平较高患者群体的数据,以确定最佳治疗人群 [23][24] - 公司正在努力优化基因编辑载体的配方,以提高疗效和安全性 [25][26][27]

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Samarth Kulkarni Yes, for those who are not familiar with CASGEVY, this is a product where it's an ex vivo cell therapy product. We take patient cells, edit them using CRISPR/Cas9 to produce fetal hemoglobin and the elevated fetal hemoglobin makes up for the deficiency or defectiveness of the adult beta globin. And this was an approach that ...